Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases?

Publisher Website
Google Scholar
Abstract
Lung inflammatory diseases, such as acute lung injury (ALI), asthma, chronic obstructive pulmonary disease (COPD) and lung fibrosis, represent a major health problem worldwide. Although glucocorticoids are the most potent anti‐inflammatory drug in asthma, they exhibit major side effects and have poor activity in lung inflammatory disorders such as ALI or COPD. Therefore, there is growing need for the development of alternative or new therapies to treat inflammation in the lung. Peroxisome proliferator‐activated receptors (PPARs), including the three isotypes PPARα , PPARβ (or PPARδ ) and PPARγ , are transcription factors belonging to the nuclear hormone receptor superfamily. PPARs, and in particular PPARα and PPARγ , are well known for their critical role in the regulation of energy homeostasis by controlling expression of a variety of genes involved in lipid and carbohydrate metabolism. Synthetic ligands of the two receptor isotypes, the fibrates and the thiazolidinediones, are clinically used to treat dyslipidaemia and type 2 diabetes, respectively. Recently however, PPARα and PPARγ have been shown to exert a potent anti‐inflammatory activity, mainly through their ability to downregulate pro‐inflammatory gene expression and inflammatory cell functions. The present article reviews the current knowledge of the role of PPARα and PPARγ in controlling inflammation, and presents different findings suggesting that PPARα and PPARγ activators may be helpful in the treatment of lung inflammatory diseases.

This publication has 177 references indexed in Scilit: